Association Between SGLT2 Inhibitors and DPP ‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Documenti analoghi

• Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
  di: Myung Jin Kim, et al.
  Pubblicazione: (2025)
• Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison
  di: Ji Eun Jun, et al.
  Pubblicazione: (2026)
• Interrelationship Between Baseline HbA1c , SGLT ‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis
  di: Samuel Seidu, et al.
  Pubblicazione: (2026)
• Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function
  di: Hiroki Nobayashi, et al.
  Pubblicazione: (2026)
• Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial
  di: Yun Kyung Cho, et al.
  Pubblicazione: (2025)